NCNA - ニュ―カナ （NuCana plc） ニュ―カナNCNAのチャート
NCNAの企業情報
| symbol | NCNA |
|---|---|
| 会社名 | NuCana Plc （ニュ―カナ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 NuCana PLC is a clinical-stage biopharmaceutical company. The Company is focused on improving treatment outcomes for cancer patients by applying its phosphoramidate chemistry technology. The Company utilizes its ProTide technology to develop medicines to overcome cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline of products includes Acelarin NUC-3373 and NUC-7738. Acelarin is a nucleotide analog and is a ProTide transformation of gemcitabine for the treatment of cancer. The Company is evaluating Acelarin in four clinical trials across several solid tumor indications. NUC-3373 is a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil for the treatment of a wide range of cancers. NUC-3373 is in a Phase I trial for the potential treatment of a wide range of solid tumor cancers. NUC-7738 is a ProTide transformation of cordycepin a novel nucleoside analog. ニュ―カナはイギリスのバイオ医薬品企業。臨床段階で、がん治療の医薬品ポ―トフォリオの開発に従事する。主に卵巣がん、胆道がん、膵臓がん、結腸直腸がん、乳がん、血液のがんに対する治療薬を開発、英国と米国で事業を展開する。同社独自のプラットフォ―ム技術を利用し、抗がん剤を製造する。本社所在地はエディンバラ。 NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer by applying its ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid and hematological tumors, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated. Utilizing its proprietary technology, the company is developing new medicines, ProTides, designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. NuCana's robust pipeline includes three ProTides in clinical development. Acelarin and NUC-3373, are new chemical entities derived from the nucleoside analogs gemcitabine and 5-fluorouracil, respectively, two widely used chemotherapy agents. Acelarin is in a Phase III study for patients with advanced biliary tract cancer and a Phase III study for patients with metastatic pancreatic cancer for which enrollment has been suspended. NUC-3373 is in a Phase I study for the potential treatment of a wide range of patients with advanced solid tumors and a Phase Ib study for patients with metastatic colorectal cancer. Its third ProTide, NUC-7738, is a transformation of a novel nucleoside analog (3'-deoxyadenosine) and is in a Phase I study for patients with advanced solid tumors. |
| 本社所在地 | 3 Lochside Way Edinburgh EH12 9DT GBR |
| 代表者氏名 | Christopher B. Wood クリストファーB.ウッド |
| 代表者役職名 | Chairman of the Board Co-Founder_Chief Medical Officer |
| 電話番号 | +44 131-248-3660 |
| 設立年月日 | 35462 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2017年 |
| 従業員数 | 20人 |
| url | www.nucana.com |
| nasdaq_url | https://www.nasdaq.com/symbol/ncna |
| adr_tso | 8945249 |
| EBITDA | EBITDA（百万ドル） -38.10040 |
| 終値（lastsale） | 20.89 |
| 時価総額（marketcap） | 186866251.61 |
| 時価総額 | 時価総額（百万ドル） 645.76620 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） ー |
| 当期純利益 | 当期純利益（百万ドル） -34.52053 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 NuCana PLC (ADR) revenues was not reported. Net loss increased 76% to ￡7.7M. Higher net loss reflects Research and development expenses increase from ￡3.7M to ￡8.9M (expense) Administrative expenses increase from ￡637K to ￡2.6M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -￡0.14 to -￡0.24. |
NCNAのテクニカル分析
NCNAのニュース
NuCana plc: NuCana Presents Data at the AACR 2023 Annual Meeting Highlighting Novel NUC-7738 Mechanisms of Action 2023/04/14 12:10:00 Finanz Nachrichten
NUC-7738 Reduces Secreted Forms of PD-L1 Indicating Potential Synergy with Checkpoint Inhibitors NUC-7738 Decreases Glutaminase in vitro and in Cancer Tissue Demonstrating Potential for Anti-Cancer…
NuCana plc: NuCana Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Business Update 2023/04/04 20:10:00 Finanz Nachrichten
Multiple Important Data Readouts Expected in 2023 Well Capitalized with Anticipated Cash Runway into 2025 EDINBURGH, United Kingdom, April 04, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) ann…
Why Is Near Intelligence (NIR) Stock Down 17% Today? 2023/03/27 13:42:21 InvestorPlace
Near Intelligence (NASDAQ: NIR ) stock is on the move Monday as the company’s shares continue to fluctuate following its public debut . Near Intelligence went public last week when it combined with special purpose acquisition company (SPAC) Kludein I Acquisition. The merger was completed on Thursday with shares of the company’s stock starting to trade on Friday. During its first day of trading, shares of NIR stock rose roughly 12%. However, today’s movement has the company more than giving up the gains it made during its public debut. It’s worth noting investors often see volatility in a stock shortly after it goes public. In the case of NIR stock, it’s taking a 17.3% beating as of Monday morning. That comes alongside some 20,000 shares changing hands. That’s not much compared to its prior daily trading volume of around 77,000 shares. What Is Near Intelligence? Near Intelligence is a data intelligence company focused on its software-as-a-service (SaaS) platform. This has it offering up information on consumers to companies to help them better curate customer experiences.
Why Is NuCana (NCNA) Stock Down 36% Today? 2023/03/27 13:21:43 InvestorPlace
NuCana (NASDAQ: NCNA ) stock is sliding lower on Monday after the company got an unfortunate update from the Technical Board of Appeal (TBA) of the European Patent Office (EPO). The bad news for investors in NCNA stock is the TBA has determined that the company’s European Patent 2955190 isn’t valid. This follows up a similar ruling last week that invalidated the patent in the U.K. Hugh Griffith, founder and CEO of NuCana, said the following about the TBA’s decision. “While we are disappointed by these decisions, they do not impact our core business of developing innovative new medicines for the treatment of patients with cancer. NuCana is well-capitalized, all of our clinical programs remain on track and we expect multiple data announcements in 2023.” How This Affects NCNA Stock Investors in NCNA stock aren’t reacting well to the patent news. As a result, the company’s stock is seeing heavy trading as shareholders sell the stock. For the record, that has some 200,000 shares trading hands as of this writing.
NuCana plc: Technical Board of Appeal of the European Patent Office Issues Oral Ruling that NuCana''s ''190 Patent is Not Valid 2023/03/24 20:34:00 Finanz Nachrichten
Ruling Has No Impact on NuCana''s Anti-Cancer ProTide PatentsMUNICH, Germany, March 24, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that, following a hearing on March 24, 2023, the …
Why Is Near Intelligence (NIR) Stock Down 17% Today? 2023/03/27 13:42:21 InvestorPlace
Near Intelligence (NASDAQ: NIR ) stock is on the move Monday as the company’s shares continue to fluctuate following its public debut . Near Intelligence went public last week when it combined with special purpose acquisition company (SPAC) Kludein I Acquisition. The merger was completed on Thursday with shares of the company’s stock starting to trade on Friday. During its first day of trading, shares of NIR stock rose roughly 12%. However, today’s movement has the company more than giving up the gains it made during its public debut. It’s worth noting investors often see volatility in a stock shortly after it goes public. In the case of NIR stock, it’s taking a 17.3% beating as of Monday morning. That comes alongside some 20,000 shares changing hands. That’s not much compared to its prior daily trading volume of around 77,000 shares. What Is Near Intelligence? Near Intelligence is a data intelligence company focused on its software-as-a-service (SaaS) platform. This has it offering up information on consumers to companies to help them better curate customer experiences.
Why Is NuCana (NCNA) Stock Down 36% Today? 2023/03/27 13:21:43 InvestorPlace
NuCana (NASDAQ: NCNA ) stock is sliding lower on Monday after the company got an unfortunate update from the Technical Board of Appeal (TBA) of the European Patent Office (EPO). The bad news for investors in NCNA stock is the TBA has determined that the company’s European Patent 2955190 isn’t valid. This follows up a similar ruling last week that invalidated the patent in the U.K. Hugh Griffith, founder and CEO of NuCana, said the following about the TBA’s decision. “While we are disappointed by these decisions, they do not impact our core business of developing innovative new medicines for the treatment of patients with cancer. NuCana is well-capitalized, all of our clinical programs remain on track and we expect multiple data announcements in 2023.” How This Affects NCNA Stock Investors in NCNA stock aren’t reacting well to the patent news. As a result, the company’s stock is seeing heavy trading as shareholders sell the stock. For the record, that has some 200,000 shares trading hands as of this writing.
NuCana plc: Technical Board of Appeal of the European Patent Office Issues Oral Ruling that NuCana''s ''190 Patent is Not Valid 2023/03/24 20:34:00 Finanz Nachrichten
Ruling Has No Impact on NuCana''s Anti-Cancer ProTide PatentsMUNICH, Germany, March 24, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that, following a hearing on March 24, 2023, the …
NuCana: Pipeline And Major Gilead Litigation Progressing Nicely (NASDAQ:NCNA) 2023/01/08 09:30:40 Seeking Alpha
NuCana’s market cap is not reflecting potential of two other drug candidates NUC-3373 and NUC-7738, currently in Phase 2 trials. See why I rate NCNA stock a strong buy.
NuCana plc: NuCana Announces Receipt of NASDAQ Notice 2023/01/06 21:10:00 Finanz Nachrichten
EDINBURGH, United Kingdom, Jan. 06, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that it received written notification (the "Notification Letter") from The Nasdaq Stock Market LLC …
NuCana: Pipeline And Major Gilead Litigation Progressing Nicely (NASDAQ:NCNA) 2023/01/08 09:30:40 Seeking Alpha
NuCana’s market cap is not reflecting potential of two other drug candidates NUC-3373 and NUC-7738, currently in Phase 2 trials. See why I rate NCNA stock a strong buy.
NuCana plc: NuCana Announces Receipt of NASDAQ Notice 2023/01/06 21:10:00 Finanz Nachrichten
EDINBURGH, United Kingdom, Jan. 06, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that it received written notification (the "Notification Letter") from The Nasdaq Stock Market LLC …
NuCana plc: NuCana Presents Positive Data on NUC-3373 at the 34th EORTC-NCI-AACR Annual Meeting 2022 2022/10/26 11:05:00 Finanz Nachrichten
NUC-3373 Potentiates Immunogenic Activity in Lung Cancer Cells Pembrolizumab Activity Increased by NUC-3373 in Lung Cancer Cells NuCana has Initiated the NuTide:303 Study of NUC-3373 in Combination…
NuCana Stock: An Intriguing ''Sum Of The Parts'' Story (NASDAQ:NCNA) 2022/09/22 19:40:03 Seeking Alpha
At current trading levels, NCNA seems to be a speculative but compelling SOTP story. It would seem to merit a small "watch item" position in diversified biotech portfolio. Read more here.
NuCana plc: NuCana Presents Promising Data on NUC-7738 at the European Society of Medical Oncology (ESMO) Annual Meeting 2022 2022/09/12 15:29:00 Finanz Nachrichten
NUC-7738 Demonstrates Encouraging Anti-Tumor Activity and a Favorable Safety Profile Across a Variety of Solid Tumors NUC-7738 Monotherapy and Combination with Pembrolizumab to be Investigated in P…